Showing results (21-30 of 154) with videos related to
Sort By:
Pageof 16
Seminars in Oncology|May 29, 1999
Dosing considerations with amifostine: a review of the literature and clinical experienceR T Dorr, B C HolmesAnticancer Research|September 1, 1994
Effect of doxorubicin on glutathione and glutathione-dependent enzymes in cultured rat heart cellsN S Paranka, R T DorrCancer Chemotherapy and Pharmacology|January 1, 1991
Modulation of mitomycin C-induced multidrug resistance in vitroR T Dorr, J D LiddilCancer Treatment Reports|November 1, 1981
Pharmacologic antidotes to experimental doxorubicin skin toxicity: a suggested role for beta-adrenergic compoundsR T Dorr, D S AlbertsJournal of Cancer Research and Clinical Oncology|January 1, 1989
H2-antagonists and carmustineR T Dorr, M J SobleAnticancer Research|January 1, 1988
Lack of enhanced antitumor efficacy for L-buthionine sulfoximine in combination with carmustine, cyclophosphamide, doxorubicin or melphalan in miceM J Soble, R T DorrCancer|August 15, 1992
Topical absorption and inactivation of cytotoxic anticancer agents in vitroR T Dorr, D S AlbertsInvestigational New Drugs|January 1, 1983
Skin ulceration potential without therapeutic anticancer activity for epipodophyllotoxin commercial diluentsR T Dorr, D S AlbertsCancer Research|June 1, 1981
Modulation of experimental doxorubicin skin toxicity by beta-adrenergic compoundsR T Dorr, D S AlbertsCancer Treatment Reviews|January 1, 1995
Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal functionP E Kintzel, R T DorrPageof 16